The use of 18FDG PET in NSCLC

Postmus, P.E. [Promotor]Teule, G.J.J. [Promotor]Hoekstra, O.S. [Copromotor]Smit, E.F. [Copromotor

Practical management of NSCLC patients with long-term bevacizumab treatment: A report of four cases

Introduction: Previous research showed that the addition of bevacizumab (a monoclonal antibody against vascular endothelial growth factor [VEGF]) to chemotherapy resulted i

A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus

Aim: Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular disease (CVD) linked to atherogenic dyslipidaemia and postprandial hyperlipidaemia. Alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, improves CVD risk by reducing the concentration of low-density lipoprotein-cholesterol (LDL-C). However, effects of PCK9 inhibitors on other aspects of diabetic dyslipidaemia, particularly in the postprandial situation, are less clear. Material and Methods: Twelve male patients with T2DM on an intensive insulin regimen completed a 6-week randomized, double-blind, placebo-controlled, proof-of-concept study. Participants received three biweekly dosages of subcutaneous alirocumab (150 mg) or placebo. Before and after the intervention, fasting and postprandial triglyceride (TG) plasma levels, apolipoprotein (apo) B48, lipoprotein composition isolated by ultracentrifugation, vascular function and markers of inflammation were evaluated. Results: Alirocumab treatment reduced fasting plasma TG levels (between group median change −24.7%; P = 0.018) and fasting apoB48 serum levels (−35.9%; P = 0.039) compared with placebo. Alirocumab reduced the plasma TG area under the curve (AUC) (−26.4%; P = 0.006) and apoB48 AUC (−55.7%; P = 0.046), as well as plasma TG incremental AUC (−21.4%; P = 0.04) and apoB48 incremental AUC (−26.8%; P = 0.02). In addition, alirocumab reduced fasting and postprandial TG levels in very low-density lipoprotein (VLDL) and LDL. Alirocumab improved fasting pulse wave velocity, but no changes in postprandial markers of inflammation were observed. Conclusions: In addition to the well-known LDL-C-reducing effects, 6 weeks of alirocumab treatment lowered both fasting and postprandial plasma TG levels by reducing the TG levels in VLDL and LDL and the concentration of intestinal remnants

Docking Robustness of Patient Specific Surgical Guides for Joint Replacement Surgery

Optimising joint reconstruction management in arthritis and bone tumour patient

Decentrale, duurzame energiesystemen en -opslag

Nederland staat voor de uitdaging om de energievoorziening duurzaam te maken, dat wil zeggen dat we op termijn naar een energiesysteem moeten dat CO2-neutraal is. Een energiesysteem waarbij grootschalige, centrale opwekking efficiënt gecombineerd wordt met decentrale, kleinschaliger opwekking. Een belangrijke uitdaging daarbij is dat bij decentrale opwekking, uit bijvoorbeeld wind en zon, sprake is van een fluctuerend aanbod van energie, dat niet altijd en overal precies past op de vraag. Hiervoor zijn, anders dan in het huidige systeem, technieken zoals decentrale aanbodsturing en opslag van energie nodig. Daarbij gaat het dan om opslag van energie voor lange en korte periodes (denk aan seizoenseffecten of fluctuaties die op één dag plaatsvinden)

Shaping Patient Specific Surgical Guides for Arthroplasty to Obtain High Docking Robustness

Optimising joint reconstruction management in arthritis and bone tumour patient